

O P E JCAT
APR 04 2002

Page 1 of 2

Substitute Form PTO-1449 PATENT & TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket	SUN-66P
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Roger Briesewitz	
		Application Number	09/316,932	
		Filing Date	May 21, 1999	
		Group Art Unit	1646	

TECH CENTER 1600
ATR 09/2002
16012000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>an</i>	AA-1	5,830,462	11/3/98	Crabtree, et al.	424	93.21	6/7/95
<i>an</i>	AB-1	5,834,266	11/10/98	Crabtree, et al.	435	172.3	8/18/94
<i>an</i>	AC-1	5,840,733	11/24/98	Krantz, et al.	514	311	7/1/96
<i>an</i>	AD-1	5,843,440	12/1/98	Pouletty, et al.	424	133.1	8/14/96
<i>an</i>	AE-1	5,869,337	2/9/99	Crabtree, et al.	435	372.3	2/14/95
<i>an</i>	AF-1	5,871,753	2/16/99	Crabtree, et al.	424	280.1	6/7/95

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>an</i>	AG-1	91/01743	2/21/91	WO				
<i>an</i>	AH-1	94/18317	8/18/94	WO				
<i>an</i>	AI-1	95/02684	1/26/95	WO				
<i>an</i>	AJ-1	95/05389	2/23/95	WO				
<i>an</i>	AK-1	95/10302	4/20/95	WO				
<i>an</i>	AL-1	96/06111	2/29/96	WO				
<i>an</i>	AM-1	96/12796	5/2/96	WO				
<i>an</i>	AN-1	97/25074	7/17/97	WO				
<i>an</i>	AO-1	97/29372	8/14/97	WO				
<i>an</i>	AP-1	98/00171	1/8/98	WO				
<i>an</i>	AQ-1	98/11437	3/19/98	WO				
<i>an</i>	AR-1	98/46270	10/22/98	WO				

EXAMINER <i>an</i>	U. V. T.	DATE CONSIDERED <i>3/20/03</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

	AS-1	98/47002	10/22/98	WO			
OTHER DOCUMENTS (including Author, Title, Date, Place of Publication)							
<i>IP E</i> APR 04 2002	AT-1	Atwell, John L., et al., "Design and Expression of a Stable Bispecific scFv Dimer With Affinity for Both Glycophorin and N9 Neuraminidase," <i>Molecular Immunology</i> (1996) Vol. 22, No. (17/18):1301-1312.					
<i>SEARCHED</i> TRADE SHOW	AU-1	Bernstein, Kenneth E., et al., "A Deeply Recessed Active Site in Angiotensin-Converting Enzyme Is Indicated From the Binding Characteristics of Biotin-Spacer-Inhibitor Reagents," <i>Biochemical and Biophysical Communications</i> (Feb. 28, 1990) Vol. 167, No. (1):310-316.					
<i>an</i>	AV-1	Bourdouxhe-Housiaux, Catherine, et al., "Interaction of DNA-Threading Peptide-Amsacrine Conjugates With DNA and Chromatin," <i>Anti-Cancer Drug Design</i> (1996) Vol. 11:509-525.					
<i>an</i>	AW-1	Chakraborty, TK., et al., "Design and Synthesis of a Rapamycin-Based High Affinity Binding FKBP12 Ligand," <i>Chemistry & Biology</i> (March 1995) Vol. 2:157-161.					
<i>an</i>	AX-1	Crabtree, Gerald R., et al., "Three-Part Inventions: Intracellular Signalling and Induced Proximity," <i>Elsevier Trends Journal</i> (Nov. 1996) pp:418-422.					
<i>an</i>	AY-1	Ho, Steffan N., et al., "Dimeric Ligands Define a Role for Transcriptional Activation Domains In Reinitiation," <i>Nature</i> (Aug. 29, 1996) Vol. 382, No. (6594):822-826.					
<i>an</i>	AZ-1	Kramer, Werner, et al., "Liver-Specific Drug Targeting by Coupling to Bile Acids," <i>The Journal of Biological Chemistry</i> (1992) Vol. 267, No. (2):18598-18604.					
<i>an</i>	BA-1	Mogre, R.M., et al., "A New Carbene Based Heterobifunctional Reagent: Photochemical Crosslinking of Aldolase," <i>FEBS Letters</i> (Sept. 1987) Vol. 221, No. (2):408-414.					
<i>an</i>	BB-1	Mu, Yu., et al., "Bioconjugation of Laminin Peptide YIGSR With Poly(Styrene Co-Maleic Acid) Increases Its Antimetastatic Effect on Lung Metastasis of B16-BL6 Melanoma Cells," <i>Biochemical and Biophysical Research Communications</i> (1999) Vol. 255:75-79.					
<i>an</i>	BC-1	Varshavsky, Alexander, "Codominant Interference, Antieffectors, and Multitarget Drugs," <i>Proc. Natl. Acad. Sci. USA</i> (March 1998) Vol. 95:2094-2099.					
<i>an</i>	BD-1	Varshavsky, Alexander, "Codominance and Toxins: A Path to Drugs of Neatly Unlimited Selectivity," <i>Proc. Natl. Acad. Sci. USA</i> (April 1995) Vol. 92:3663-3667.					

F:\DOCUMENT\Stanford (SUN)\66p\PTO-1449 Form.wpd

TECH CENTER 1600/2900

APR 09 2002

RECEIVED

EXAMINER	<i>an</i>	DATE CONSIDERED	3/20/03
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) Use several sheets if necessary APR 04 2002	ATTY. DOCH. NO.	SERIAL NO.
	SUN-66P	09/316,932
	APPLICANT	
Briesewitz, et al.		TECH CENTER 1645
FILING DATE		GROUP
May 21, 1999		1645

RECEIVED
APR 9 2002
U.S. PATENT AND TRADEMARK OFFICE
1600/29

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
DA	AA-1 5,382,657	01-17-95	Karasiewicz, et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes
DA	AB-1 WO 98/47916	10-29-98	PCT			No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DA	AC-1	Al-Obeidi, et al., (1990) "Synthesis and Actions of a Melanotropin Conjugate, Ac-[Nle ⁴ , Glu(gamma-4'-hydroxyanilide) ⁵ , D-Phe ⁷]α-MSH ₄₋₁₀ -NH ₂ , on Melanocytes and Melanoma Cells In Vitro," <i>Journal of Pharmaceutical Sciences</i> Vol. 79, No. (6):500-504.
DA	AD-1	Belshaw, et al., (1996) "Controlling Protein Association and Subcellular Localization with a Synthetic Ligand that Induces Heterodimerization of Proteins," <i>Proc. Natl. Acad. Sci. U.S.A.</i> Vol. 93:4604-4607.
DA	AE-1	Brochu, et al., (1992) "Modes of Action and Inhibitory Activities of New Siderophore-β-Lactam Conjugates that use Specific Iron Uptake Pathways for Entry into Bacteria," <i>Antimicrobial Agents and Chemotherapy</i> Vol. 36, No. (10):2166-2175.
DA	AF-1	Briesewitz, et al., (1999) "Affinity Modulation of Small-Molecule Ligands by Borrowing Endogenous Protein Surfaces," <i>P.N.A.S</i> Vol. 96, No. (5):1953-1958.
DA	AG-1	Heath, et al., (1986) "Liposome-Mediated Delivery of Pteridine Antifolates to cells in Vitro: Potency of Methotrexate, and its α and γ Substituents," <i>Biochimica et Biophysica Acta</i> Vol. 862:72-80.
DA	AH-1	Holt, et al., (1994) "Structure-Activity Studies of Synthetic FKBP Ligands as Peptidyl-Prolyl Isomerase Inhibitors," <i>Bioorganic and Medicinal Chemistry Letters</i> Vol. 4, No. (2):315-320.
DA	AI-1	Luengo, et al., (1994) "Synthesis and Structure-Activity Relationships of Macrocyclic FKBP Ligands," <i>Bioorganic and Medicinal Chemistry Letters</i> Vol. 4, No. (2):321-324.
DA	AJ-1	Lussow, et al., (1996) "Targeting of Antihapten Antibodies to Activated T Cells via an IL-2-Hapten Conjugate Prolongs Cardiac Graft Survival," <i>Transplantation</i> Vol. 62, No. (12):1703-1708.
DA	AK-1	Maeda, et al., (1997) "Amino Acids and Peptides XXXII: A Biofunctional Poly(Ethylene Glycol) Hybrid of Fibronectin-Related Peptides," <i>Biochemical and Biophysical Research Communications</i> Vol. 241:595-598.
DA	AL-1	Zunino, et al., (1984) "Compassion of Antitumor Effects of Daunorubicin Covalently Linked to Poly-L-Amino Acid Carriers," <i>Eur. J. Cancer Chem. Oncol.</i> Vol. 20, No. (3):421-425.

EXAMINER	M. <i>[Signature]</i>	DATE CONSIDERED	3/20/03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			